News
PRPH
0.3030
-0.33%
-0.0010
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1
NASDAQ · 5d ago
Weekly Report: what happened at PRPH last week (0428-0502)?
Weekly Report · 5d ago
Weekly Report: what happened at PRPH last week (0421-0425)?
Weekly Report · 04/28 09:52
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 04/21 12:10
Weekly Report: what happened at PRPH last week (0414-0418)?
Weekly Report · 04/21 09:51
Weekly Report: what happened at PRPH last week (0407-0411)?
Weekly Report · 04/14 09:48
Weekly Report: what happened at PRPH last week (0331-0404)?
Weekly Report · 04/07 09:48
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 04/04 17:06
ProPhase Labs Delays Yearly Report Filing
TipRanks · 04/01 12:19
Prophase Labs Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 04/01 11:26
ProPhase Labs Reports 2024 Financial Results and Strategic Shift
TipRanks · 04/01 03:56
ProPhase Labs Earnings Call: Strategic Moves Amid Financial Challenges
TipRanks · 04/01 00:04
ProPhase Labs FY24 EPS $(2.61) Misses $(1.27) Estimate, Sales $6.80M Miss $13.02M Estimate
Benzinga · 03/31 12:16
*ProPhase Labs 2024 Rev $6.8M Vs. $35M >PRPH
Dow Jones · 03/31 12:08
ProPhase Labs GAAP EPS of -$2.61
Seeking Alpha · 03/31 12:04
BRIEF-ProPhase Labs FY Net Income USD -53.364 Million
Reuters · 03/31 12:00
PROPHASE LABS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024
Reuters · 03/31 12:00
Weekly Report: what happened at PRPH last week (0324-0328)?
Weekly Report · 03/31 09:52
Earnings Scheduled For March 31, 2025
Benzinga · 03/31 08:32
ProPhase Labs FY 2024 Earnings Preview
Seeking Alpha · 03/28 22:35
More
Webull provides a variety of real-time PRPH stock news. You can receive the latest news about Prophase Labs Inc through multiple platforms. This information may help you make smarter investment decisions.
About PRPH
More
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.